Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells

Experimental Cell Research

Volumn 312, Issue 17, 2006, Pages 3370-3378

  Duan, Wenrui ^a   Gao, Li ^a   Wu, Xin ^a   Zhang, Yang ^a   Otterson, Gregory A ^a   Villalona Calero, Miguel A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Lung cancer; MDM2; p53; Pirh2; Ubiquitin

Indexed keywords

CISPLATIN; DNA; PIRH 2 PROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GAMMA IRRADIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG PARENCHYMA; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSACTIVATION; TUMOR CELL; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

MURINAE;

EID: 33748604311     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.07.005     Document Type: Article

References (47)

1. Farmer G., Bargonetti J., Zhu H., Friedman P., Prywes R., and Prives C. Wild-type p53 activates transcription in vitro. Nature 358 (1992) 83-86
2. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
3. 1 cyclin-dependent kinases. Cell 75 (1993) 805-816
4. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
5. Vousden K.H. p53: death star. Cell 103 (2000) 691-694
6. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
7. Hernandez-Boussard T., Rodriguez-Tome P., Montesano R., and Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. Hum. Mutat. 14 (1999) 1-8
8. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
9. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., and Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science 252 (1991) 1708-1711
10. Deng Y., and Wu X. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12050-12055
11. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., and Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377 (1995) 552-557
12. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev. 10 (1996) 1054-1072
13. Tarapore P., and Fukasawa K. Loss of p53 and centrosome hyperamplification. Oncogene 21 (2002) 6234-6240
14. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
15. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., and Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4 (1994) 1-7
16. Fakharzadeh S.S., Trusko S.P., and George D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10 (1991) 1565-1569
17. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 (1992) 80-83
18. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
19. Kubbutat M.H., Jones S.N., and Vousden H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
20. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 (1997) 25-27
21. Barak Y., Juven T., Haffner R., and Oren M. MDM2 expression is induced by wild type p53 activity. EMBO J. 12 (1993) 461-468
22. Perry M.E., Piette J., Zawadzki J.A., Harvey D., and Levine A.J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 11623-11627
23. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362 (1993) 857-860
24. Chen C.Y., Oliner J.D., Zhan Q., Fornace Jr. A.J., Vogelstein B., and Kastan M.B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 2684-2688
25. Chen J., Wu X., Lin J., and Levine A.J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16 (1996) 2445-2452
26. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
27. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J.M., Lozano G., Hakem R., and Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112 (2003) 779-791
28. Logan I.R., Sapountzi V., Gaughan L., Neal D.E., and Robson C.N. Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J. Biol. Chem. 279 (2004) 11696-11704
29. Duan W., Gao L., Druhan L.J., Zhu W.G., Morrison C., Otterson G.A., and Villalona-Calero M.A. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl. Cancer Inst. 96 (2004) 1718-1721
30. Ding H., Duan W., Zhu W.G., Ju R., Srinivasan K., Otterson G.A., and Villalona-Calero M.A. P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochem. Biophys. Res. Commun. 305 (2003) 950-956
31. Zhu W.G., Hileman T., Ke Y., Wang P., Lu S., Duan W., Dai Z., Tong T., Villalona-Calero M.A., Plass C., and Otterson G.A. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J. Biol. Chem. 279 (2004) 15161-15166
32. Duan W., Ding H., Zhu W.G., Srinivasan K., Otterson G.A., and Villalona-Calero M.A. RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. Biotechniques 33 (2002) 58-66
33. Duan W., Ding H., Subler M.A., Zhu W.G., Zhang H., Stoner G.D., Windle J.J., Otterson G.A., and Villalona-Calero M.A. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21 (2002) 7831-7838
34. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
35. Zambetti G.P., and Levine A.J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7 (1993) 855-865
36. Kondo S., Barna B.P., Kondo Y., Tanaka Y., Casey G., Liu J., Morimura T., Kaakaji R., Peterson J.W., Werbel B., and Barnett G.H. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 13 (1996) 1279-1285
37. Allday M.J., Sinclair A., Parker G., Crawford D.H., and Farrell P.J. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J. 14 (1995) 1382-1391
38. Shaulian E., Resnitzky D., Shifman O., Blandino G., Amsterdam A., Yayon A., and Oren M. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 15 (1997) 2717-2725
39. El-Deiry W.S., Tokino T., Waldman T., Oliner J.D., Velculescu V.E., Burrell M., Hill D.E., Healy E., Rees J.L., and Hamilton S.R. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55 (1995) 2910-2919
40. El-Deiry W.S. Regulation of p53 downstream genes. Semin. Cancer Biol. 8 (1998) 345-357
41. Perry M.E. Mdm2 in the response to radiation. Mol. Cancer Res. 2 (2004) 9-19
42. Beitel L.K., Elhaji Y.A., Lumbroso R., Wing S.S., Panet-Raymond V., Gottlieb B., Pinsky L., and Trifiro M.A. Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J. Mol. Endocrinol. 29 (2002) 41-60
43. Zhang L., Li J., Wang C., Ma Y., and Huo K. A new human gene hNTKL-BP1 interacts with hPirh2. Biochem. Biophys. Res. Commun. 330 (2005) 293-297
44. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., and Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004) 86-92
45. Dornan D., Bheddah S., Newton K., Ince W., Frantz G.D., Dowd P., Koeppen H., Dixit V.M., and French D.M. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 64 (2004) 7226-7230
46. Fuchs S.Y., Adler V., Buschmann T., Yin Z., Wu X., Jones S.N., and Ronai Z. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12 (1998) 2658-2663
47. Zhang Z., Li M., Wang H., Agrawal S., and Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad Sci. U. S. A. 100 (2003) 11636-11641